Dr Hageman talks to Prof Gordon McVie about the microenvironment. He discusses how to address the clinical questions but also how to target specific cells, which are not malignant in the tumour microenvironment. Dr Hageman goes on to explain why Ipilimumab is such good news for treatment. He talks about how to target the myeloid suppression system, with regard to specific signalling pathways and specific cell surface markers. Dr Hageman ends the interview with a call for a combined approach targeting innate immunity and adaptive immunity with Ipilimumab.